Loading patent…
OwnerAoife Brennan, Caroline Kurtz +3inventors
InventorsAoife Brennan, Caroline Kurtz, Neal Sondheimer, Michael James, David Lubkowicz
Estimating the term…
The present disclosure provides recombinant bacterial cells that have been engineered with genetic circuitry which allow the recombinant bacterial cells to sense a patient's internal environment and respond by turning an engineered metabolic pathway on or off. When turned on, the recombinant bacterial cells complete all of the steps in a metabolic pathway to achieve a therapeutic effect in a host subject. These recombinant bacterial cells are designed to drive therapeutic effects throughout the body of a host from a point of origin of the microbiome. Specifically, the present disclosure provides recombinant bacterial cells that comprise a methionine decarboxylase enzyme for the treatment of diseases and disorders associated with amino acid metabolism, including homocystinuria, in a subject. The disclosure further provides pharmaceutical compositions and methods of treating disorders associated with amino acid metabolism, such as homocystinuria
A method of treating a disease associated with methionine metabolism in a human subject, the method comprising orally administering to the subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a recombinant bacterium, wherein the recombinant bacterium is an E. coli Nissle bacterium comprising:
(canceled)
-12. (canceled)
-15. (canceled)
-21. (canceled)
-24. (canceled)
-28. (canceled)
-37. (canceled)
-48. (canceled)
A pharmaceutical composition comprising a pharmaceutically acceptable carrier, 25 mM to 100 mM Tris, 5%-15% trehalose, pH 6.0-8.0, and a recombinant bacterium,
A pharmaceutical composition comprising a pharmaceutically acceptable carrier, a recombinant bacterium, and vitamin B6, pyridoxal 5 phosphate, and/or pyridoxine,
(canceled)
Dependencies are inferred from the claim text.